Page 40 - Planegg News Today

During the continued progression of the Corona pandemic, rapid, inexpensive, and reliable tests will become increasingly important to determine whether people have the associated antibodies - either through infection or vaccination.

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals ACCESSWIRE 17 Jun 2021, 08:31 GMT+10 PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) (MorphoSys) today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) (Constellation) for $34.00 per share, net to the seller in cash, without interest, and subject to any applicable withholding of t...

Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class

Investegate announcements from MorphoSys AG, MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billio...

BERLIN (AP) — Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival...

DGAP-News: CatalYm GmbH: CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 neutralizing antibody CTL-002 at the 2021 ASCO Annual Meeting The poster " A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER)", Abstract TPS2658 , will present CatalYms first-in-human, two-part, open-label phase 1 clinical trial of CTL-002, a neutralizing antibody targeting GDF-15. GDF-15 is a factor that is...

MUNICH, Germany, May 20, 2021 (GLOBE NEWSWIRE) -- CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that ...

MorphoSys AG: MorphoSys to Present Data on Tafasitamab (Monjuvi) at the 2021 ASCO Annual Meeting PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi (R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which was approved as M...

The company intends to use the funds to: accelerate the ongoing scale-up of its industrial projects worldwide, drive further the internationalization of its commercial activities as it continues to expand its customer base into new markets. The round was led by Novo Growth, the growth equity arm of Novo Holdings with participation from new investors Cargill and E.R. Capital Holdings as well as existing investors MIG Verwaltungs AG and ATHOS KG. In conjunction with the funding, Kartik Dharmadh...